Clinical Study

Pharmacodynamic Effect of Clopidogrel in Patients Undergoing Transcatheter Aortic Valve Implantation

Petr Tousek, Viktor Kocka, Jakub Sulzenko, Frantisek Bednar, Hana Linkova, and Petr Widimsky

Third Faculty of Medicine, Charles University, University Hospital Vinohrady, Cardiocenter, Srobarova 50, 100 34 Prague 10, Czech Republic

Correspondence should be addressed to Petr Tousek; tousek@email.cz

Received 12 April 2013; Accepted 25 June 2013

Academic Editor: Namal Wijesinghe

Copyright © 2013 Petr Tousek et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The aim of this study was to analyze periprocedural and mid-term effect of clopidogrel on platelet function using the VerifyNow P2Y₁₂ point-of-care assay in patients undergoing TAVI. Platelet reactivity was measured at the beginning of the procedure after 300 mg clopidogrel bolus administration and during the follow-up (at 1 month after the procedure) in 52 patients undergoing TAVI using the Medtronic CoreValve prosthesis (Medtronic CoreValve). A cutoff value of 240 PRU was used to identify nonresponders to clopidogrel treatment with high residual platelet reactivity (HRPR). Baseline HRPR was identified in 80% of patients and in 72% of patients during 6-month follow-up. There was no significant difference in the pharmacodynamic effects of clopidogrel on platelet reactivity from baseline to 6-months follow-up (297 ± 57 vs. 275 ± 62 ; $P = 0.058$). Ischemic event occurred only in 3 patients (5.8%) from the study group. In conclusion, majority of patients undergoing TAVI had high residual platelet reactivity after pretreatment with 300 mg of clopidogrel and during the 6-month follow-up at dual antiplatelet treatment. The noneffectiveness of clopidogrel in the TAVI population raises the question of the routine use of dual antiplatelet treatment in this setting.

1. Introduction

The number of patients with severe aortic stenosis treated with transcatheter aortic valve implantation (TAVI) is increasing worldwide. This procedure is technically feasible in the majority of patients at high risk for standard surgical management. However, special attention should be given to potential periprocedural and short-term follow-up complications. Risks associated with TAVI differ and include ischemic (stroke, myocardial infarction) or bleeding (access site complication, cardiac perforation) complications at the same time. A loading dose of 300 mg of clopidogrel before TAVI followed by dual antiaggregation therapy with 75 mg of clopidogrel for 3–6 months is generally used. This therapeutic strategy significantly decreases ischemic events after percutaneous coronary intervention (PCI) [1]. The effect of clopidogrel on platelet reactivity can be tested and high residual platelet reactivity in approximately 30% of patients after PCI is associated with increased risk of cardiovascular

death and myocardial infarction during follow-up [2, 3]. However, no data have been reported regarding the effectiveness of clopidogrel in the TAVI setting or its possible impact on adverse events. Therefore we analyzed the effect of clopidogrel on platelet function using the VerifyNow P2Y₁₂ point-of-care assay in patients undergoing TAVI.

2. Methods

We did the analysis in patients with severe aortic stenosis who underwent TAVI using the Medtronic CoreValve prosthesis (Medtronic CoreValve) between April 2009 and July 2012. All interventions were performed after pretreatment with 300 mg of clopidogrel >12 h before the procedure. Dual antiplatelet therapy with 75 mg of clopidogrel and 100 mg of acetylsalicylic acid was recommended for 6 months followed by acetylsalicylic acid alone. Platelet reactivity after clopidogrel treatment was measured by the VerifyNow P2Y₁₂ point-of-care assay (Accumetrics, San Diego, CA) at baseline (at the

beginning of the procedure) and during the follow-up (at 1 moth after the procedure). The results were expressed as P2Y₁₂ reaction units (PRU). A cutoff value of 240 PRU was used to identify non-responders to clopidogrel treatment with high residual platelet reactivity [2]. Continuous variables are expressed as mean $\pm$ standard deviation; nominal variables are expressed as count and percentages. Continuous variables were compared using the unpaired Student's *t*-test. A *P* value of *P* < 0.05 was considered significant.

3. Results

In total, 70 patients (average age 81 ± 6 years) underwent TAVI using the Medtronic CoreValve prosthesis. Baseline VerifyNow testing was successfully performed in 52 patients. In 8 patients dual antiplatelet treatment was not started due to the need of chronic oral anticoagulation and in 10 patients errors occurred during testing and thus platelet reactivity could not be assessed. Clinical characteristics of patients with baseline platelet reactivity testing are shown in Table 1. The procedure was successful in 51 patients. There were six major access site complications caused by major bleeding that required transfusion and were treated either surgically (in 3 cases) or by a conservative approach. In one patient, pericardiocentesis was performed for tamponade. Ischemic events occurred in three patients, of which one MI and one stroke occurred during the procedure and one patient suffered from stroke after discharge. One patient died during hospitalization for multiple organ failure. Mortality at 6 months was 3.8%. Baseline high residual platelet reactivity (HRPR) with PRU ≥ 240 was identified in 42 (80%) patients. Average baseline PRU was 297 ± 57 . Control VerifyNow testing was performed in 47 patients during 6-month follow-up. Thirty-four (72%) patients were assigned as nonresponsive with HRPR. Follow-up average PRU was 275 ± 62 . There was no significant difference in the pharmacodynamic effects of clopidogrel on platelet reactivity from baseline to 6-months follow-up (*P* = 0.058).

4. Discussion

A strategy of clopidogrel pretreatment followed by long-term therapy is beneficial in reducing major cardiovascular events in patients undergoing PCI [4]. Major bleeding complications in these patients differ depending on antiaggregant used and do not exceed the rate of ischemic complications [5, 6]. This is not the case for TAVI where ischemic events are much less frequent than bleeding complications. Even though cerebral imaging studies have shown a very high incidence (66%–86%) of new ischemic defects after TAVI, most defects are clinically silent [7]. The incidence of clinically apparent stroke after TAVI has an average of about 3% [7]. A German multicenter registry including 697 patients treated with TAVI indicated rates of stroke and myocardial infarction of 2.8% and 0.3%, respectively [8]. These values were comparable with FRANCE-2 registry and those reported by Piazza and by Rodés-Cabau [9–11]. On the other hand, major access site bleeding complication is the most frequent procedural

TABLE 1: Baseline characteristics of the study population (*n* = 52).

Age, years (SD)	81 (7)
Female, <i>n</i> (%)	29 (56)
BMI, kg/m ² (SD)	26.8 (5)
Logistic EuroScore, (SD)	23 (12)
Coronary artery disease, <i>n</i> (%)	28 (54)
eGFR < 60 mL/min, <i>n</i> (%)	27 (52)
Atrial fibrillation/flutter, <i>n</i> (%)	9 (17)
Previous PCI, <i>n</i> (%)	10 (19)
Previous CABG, <i>n</i> (%)	11 (21)
Previous AVR with bioprosthesis, <i>n</i> (%)	1 (3)
LVEF, % (SD)	51 (12)
LVEF < 40%	17 (32)
AVA index, cm ² /m ² (SD)	0.42 (0.08)
Femoral approach, <i>n</i> (%)	47 (90)
Subclavian approach, <i>n</i> (%)	5 (10)

complication and is present in 5%–10% of patients undergoing TAVI [7, 9–11]. Thus, special attention should be paid to reducing these procedural bleeding events. One possible issue seems to be the strategy of clopidogrel administration. As shown in our observation, the rate of ischemic events remains acceptable even if the majority of patients has HRPR at the time of procedure and follow-up. This raises the question of whether it would be beneficial to use an individual approach for clopidogrel administration (e.g., previous PCI, diffuse coronary artery disease, previous stroke, etc.). Furthermore, our results can also explain findings of two small randomized study, where the strategy of adding clopidogrel to aspirin after TAVI was not superior to aspirin alone in the six-month patients outcomes [12, 13]. Atrial fibrillation is another important comorbidity that plays role in antithrombotic strategy management. Chronic atrial fibrillation occurs approximately in one-third of patient undergoing TAVI [7]. Several antithrombotic treatment regimens after TAVI are thus under investigations in ongoing trials [13] because the optimal treatment management is still not known.

5. Conclusion

In conclusion, we found that the majority of patients undergoing TAVI had high residual platelet reactivity after pretreatment with 300 mg of clopidogrel and during the 6-month follow-up at dual antiplatelet treatment. The noneffectiveness of clopidogrel in the TAVI population raises the question of the routine use of dual antiplatelet treatment in this setting. It is important to evaluate the antiplatelet treatment strategy in patients undergoing TAVI in the large randomized study.

Acknowledgment

This work was supported by the Charles University Research Project UNCE 204010.

References

- [1] S. R. Mehta, S. Yusuf, R. J. G. Peters et al., "Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study," *The Lancet*, vol. 358, no. 9281, pp. 527–533, 2001.
- [2] R. Marcucci, A. M. Gori, R. Panizza et al., "Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay. A 12-month follow-up," *Circulation*, vol. 119, no. 2, pp. 237–242, 2009.
- [3] M. J. Price, S. Endemann, R. R. Gollapudi et al., "Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation," *European Heart Journal*, vol. 29, no. 8, pp. 992–1000, 2008.
- [4] S. R. Steinhubl, P. B. Berger, J. T. Mann III et al., "Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial," *The Journal of the American Medical Association*, vol. 288, no. 19, pp. 2411–2420, 2002.
- [5] L. Wallentin, R. C. Becker, A. Budaj et al., "Ticagrelor versus clopidogrel in patients with acute coronary syndromes," *The New England Journal of Medicine*, vol. 361, no. 11, pp. 1045–1057, 2009.
- [6] S. D. Wiviott, E. Braunwald, C. H. McCabe et al., "Prasugrel versus clopidogrel in patients with acute coronary syndromes," *The New England Journal of Medicine*, vol. 357, pp. 2001–2015, 2007.
- [7] J. Rodés-Cabau, H. L. Dauerman, M. G. Cohen et al., "Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events," *Journal of the American College of Cardiology*, 2013.
- [8] R. Zahn, U. Gerckens, E. Grube et al., "Transcatheter aortic valve implantation: first results from a multi-centre real-world registry," *European Heart Journal*, vol. 32, no. 2, pp. 198–204, 2011.
- [9] M. Gilard, H. Eltchaninoff, B. Lung et al., "Registry of transcatheter aortic-valve implantation in high-risk patients," *The New England Journal of Medicine*, vol. 366, no. 18, pp. 1705–1715, 2012.
- [10] J. Rodés-Cabau, J. G. Webb, A. Cheung et al., "Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience," *Journal of the American College of Cardiology*, vol. 55, no. 11, pp. 1080–1090, 2010.
- [11] N. Piazza, E. Grube, U. Gerckens et al., "Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval," *EuroIntervention*, vol. 4, no. 2, pp. 242–249, 2008.
- [12] G. P. Ussia, M. Scarabelli, M. Mulè et al., "Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation," *American Journal of Cardiology*, vol. 108, no. 12, pp. 1772–1776, 2011.
- [13] D. R. Lynch, D. Dantzler, M. Robbins, and D. Zhao, "Considerations in antithrombotic therapy among patients undergoing transcatheter aortic valve implantation," *Journal of Thrombosis and Thrombolysis*, vol. 35, no. 4, pp. 476–482, 2013.